Free Trial

AC Immune (ACIU) Competitors

AC Immune logo
$2.43 0.00 (0.00%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$2.44 +0.01 (+0.62%)
As of 07/25/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ACIU vs. QURE, SNDX, TRVI, MENS, NAGE, XERS, NUVB, MAZE, CRON, and KALV

Should you be buying AC Immune stock or one of its competitors? The main competitors of AC Immune include uniQure (QURE), Syndax Pharmaceuticals (SNDX), Trevi Therapeutics (TRVI), Jyong Biotech (MENS), Niagen Bioscience (NAGE), Xeris Biopharma (XERS), Nuvation Bio (NUVB), Maze Therapeutics (MAZE), Cronos Group (CRON), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry.

AC Immune vs. Its Competitors

uniQure (NASDAQ:QURE) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

uniQure has a beta of 0.08, meaning that its share price is 92% less volatile than the S&P 500. Comparatively, AC Immune has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.

AC Immune has higher revenue and earnings than uniQure. AC Immune is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
uniQure$27.12M30.52-$239.56M-$4.39-3.44
AC Immune$31.02M7.87-$57.83M-$0.58-4.19

In the previous week, uniQure had 1 more articles in the media than AC Immune. MarketBeat recorded 2 mentions for uniQure and 1 mentions for AC Immune. AC Immune's average media sentiment score of 1.91 beat uniQure's score of 0.93 indicating that AC Immune is being referred to more favorably in the news media.

Company Overall Sentiment
uniQure Positive
AC Immune Very Positive

78.8% of uniQure shares are owned by institutional investors. Comparatively, 51.4% of AC Immune shares are owned by institutional investors. 4.8% of uniQure shares are owned by insiders. Comparatively, 4.6% of AC Immune shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

AC Immune has a net margin of -177.79% compared to uniQure's net margin of -1,077.05%. AC Immune's return on equity of -44.60% beat uniQure's return on equity.

Company Net Margins Return on Equity Return on Assets
uniQure-1,077.05% -483.87% -34.28%
AC Immune -177.79%-44.60%-22.25%

uniQure currently has a consensus price target of $37.82, suggesting a potential upside of 150.29%. AC Immune has a consensus price target of $12.00, suggesting a potential upside of 393.83%. Given AC Immune's stronger consensus rating and higher possible upside, analysts clearly believe AC Immune is more favorable than uniQure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
uniQure
0 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.91
AC Immune
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

AC Immune beats uniQure on 10 of the 17 factors compared between the two stocks.

Get AC Immune News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACIU vs. The Competition

MetricAC ImmuneMED IndustryMedical SectorNASDAQ Exchange
Market Cap$244M$3.06B$5.69B$9.50B
Dividend YieldN/A2.37%4.58%4.01%
P/E Ratio-4.1921.1828.1020.05
Price / Sales7.87288.50432.4490.07
Price / CashN/A42.7636.2258.56
Price / Book1.888.378.665.87
Net Income-$57.83M-$55.19M$3.25B$258.55M
7 Day Performance17.39%5.88%4.23%3.74%
1 Month Performance16.27%17.33%10.52%11.75%
1 Year Performance-37.85%4.42%34.41%18.03%

AC Immune Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACIU
AC Immune
2.0651 of 5 stars
$2.43
flat
$12.00
+393.8%
-37.9%$244M$31.02M-4.19140Positive News
QURE
uniQure
2.2039 of 5 stars
$14.50
-3.3%
$37.82
+160.8%
+76.3%$821.09M$27.12M-3.30500Upcoming Earnings
SNDX
Syndax Pharmaceuticals
3.5291 of 5 stars
$9.73
+2.9%
$34.10
+250.5%
-60.9%$814.01M$23.68M-2.52110Positive News
TRVI
Trevi Therapeutics
3.8823 of 5 stars
$6.82
-0.6%
$20.88
+206.1%
+148.3%$804.63MN/A-15.1620
MENS
Jyong Biotech
N/A$11.00
+4.3%
N/AN/A$802.09MN/A0.0031Quiet Period Expiration
NAGE
Niagen Bioscience
1.4378 of 5 stars
$9.68
-4.7%
$13.22
+36.6%
N/A$800.69M$99.60M56.94120
XERS
Xeris Biopharma
4.006 of 5 stars
$5.14
+0.6%
$6.25
+21.6%
+96.5%$799.12M$203.07M-17.13290News Coverage
NUVB
Nuvation Bio
1.8636 of 5 stars
$2.36
+2.4%
$7.17
+204.3%
-32.3%$782.60M$7.87M-1.0060News Coverage
Analyst Upgrade
MAZE
Maze Therapeutics
N/A$16.66
-6.3%
$23.50
+41.1%
N/A$778.71M$167.50M0.00121News Coverage
Analyst Forecast
Lockup Expiration
Analyst Revision
Gap Up
High Trading Volume
CRON
Cronos Group
1.9825 of 5 stars
$2.09
+4.0%
N/A-15.3%$775.22M$117.61M16.08450News Coverage
KALV
KalVista Pharmaceuticals
3.9681 of 5 stars
$15.56
+1.1%
$26.29
+68.9%
+1.3%$768.79MN/A-4.22100

Related Companies and Tools


This page (NASDAQ:ACIU) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners